Novo Nordisk A/S, Søborg, Denmark.
Diabetes Obes Metab. 2013 Oct;15(10):958-62. doi: 10.1111/dom.12108. Epub 2013 Apr 23.
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study. Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks. Appetite ratings were assessed using visual analogue scales during a 5-h meal test. Energy and macronutrient intake during the subsequent ad libitum lunch were also measured. After 3 weeks, mean postprandial and minimum hunger ratings were significantly lower with liraglutide 1.8 mg than placebo (p < 0.01), and the mean overall appetite score was significantly higher (p = 0.05), indicating reduced appetite. Liraglutide was associated with higher maximum fullness ratings (p = 0.001) and lower minimum ratings of prospective food consumption (p = 0.01). Mean estimated energy intake was 18% lower for liraglutide than placebo [estimated ratio 0.82 (95% CI 0.73;0.94); p = 0.004], but no significant differences in macronutrient distribution were noted. Findings suggest that reduced appetite and energy intake may contribute to liraglutide-induced weight loss.
目的在于研究利拉鲁肽对 2 型糖尿病患者的食欲和能量摄入的影响，这是一项随机、安慰剂对照、双盲、交叉研究。18 名 2 型糖尿病患者被分为利拉鲁肽（每周增加 0.6mg）或安慰剂组，分别接受为期 3 周的每日一次皮下注射治疗。在 5 小时的进餐测试期间，通过视觉模拟评分法评估食欲。在随后的自由进食午餐期间，还测量了能量和宏量营养素的摄入量。经过 3 周，利拉鲁肽 1.8mg 组的餐后和最低饥饿评分明显低于安慰剂组（p<0.01），总体食欲评分明显更高（p=0.05），表明食欲下降。利拉鲁肽与更高的最大饱腹感评分相关（p=0.001），以及更低的预期食物消费最低评分相关（p=0.01）。与安慰剂相比，利拉鲁肽的估计能量摄入低 18%[估计比值 0.82（95%CI 0.73；0.94）；p=0.004]，但宏量营养素分布无显著差异。结果表明，食欲下降和能量摄入减少可能是利拉鲁肽引起体重下降的原因。
